Mar 29, 2019

NYC-based investment firm Forepont Capital Partners appointed Dr Ismail Kola as a senior partner in their venture capital Team. Dr Kola will play a key role in the conception and launch of Forepont’s next generation of pioneering biotechnology and life science companies as well as serve as an ongoing strategic resource for all companies in the Forepont ecosystem supporting their clinical development strategies. Additionally, he will serve on the board of directors of several portfolio companies and will join Forepont Capital Partners Investment Committee. Dr Kola joins Forepont from UCB, where he has served as Chief Scientific Officer since 2009. Prior to that, he was the Chief Scientific Officer at Schering Plough. During his career, he has served as Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease. Dr Kola holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, USA and Monash University Medical School, Melbourne, Australia; a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden; and is a William Pitt Fellow at Pembroke College, Cambridge University, UK. He is the holder of 10 patents and is author or co-author of 159 peer-reviewed papers and commentaries. With offices in London & Paris, Forepont Capital Partners focuses on deploys capital to fuel growth of new medicines and technologies that drive better healthcare outcomes. The firm is currently closing its second venture capital fund. FinSMEs